论文部分内容阅读
目的探讨罗格列酮片治疗2型糖尿病患者后血糖、及糖化血红蛋白及C肽(C-P)等指标的变化。结论罗格列酮治疗2型糖尿病较好的解决了长效降糖药易致低血糖的问题,安全性好。结果治疗前2组年龄、糖尿病病程、FBG、BMI的差异均无统计学意义。经12周的治疗,罗格列酮组与格列苯脲组两组之间的FBG、2HBG、HBALC、FC-P、2HC-P没有显著差异(p>0.05),但低血糖发生率罗格列酮组为4.17%,格列苯脲组为40.00%(p<0.01)。方法将2型糖尿病患者78例,随机分为两组,对罗格列酮组48例和格列苯脲治疗30例进行疗效观察。
Objective To investigate the changes of blood glucose, glycosylated hemoglobin and C-peptide (C-P) in patients with type 2 diabetes mellitus after rosiglitazone tablets treatment. Conclusion Rosiglitazone treatment of type 2 diabetes better solve the hypoglycemic problems caused by long-acting hypoglycemic agents, good safety. Results Before treatment, there were no significant differences in the age, duration of diabetes, FBG and BMI between the two groups. There was no significant difference in FBG, 2HBG, HBALC, FC-P and 2HC-P between rosiglitazone group and glibenclamide group after 12 weeks treatment (p> 0.05), but the incidence of hypoglycemia 4.17% for the glitazone group and 40.00% for the glibenclamide group (p <0.01). Methods 78 patients with type 2 diabetes mellitus were randomly divided into two groups. 48 patients were treated with rosiglitazone and 30 were treated with glibenclamide.